Neurophysiology

BrainsWay Ltd. to Host Second Quarter 2019 Financial Results Conference Call on August 26, 2019

Retrieved on: 
Wednesday, August 14, 2019
Neuroscience, Branches of biology, Brainsway, Neurophysiology, Neuropsychology, Neurotechnology, Treatment of depression, Medicine, Tel Aviv Stock Exchange, NASDAQ, GlobeNewswire, Conference call

JERUSALEM and HACKENSACK, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its second quarter 2019 financial results and operational highlights on Monday, August 26, 2019.

Key Points: 
  • JERUSALEM and HACKENSACK, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it will report its second quarter 2019 financial results and operational highlights on Monday, August 26, 2019.
  • The Company will host a conference call on Monday, August 26, 2019 at 8:00 a.m. Eastern Time to review the financial results and operational highlights.
  • The conference call will be broadcast live and will be available for replay for 30 days on the Company's website, https://investors.brainsway.com/financial-calendar.
  • Please access the Company's website at least 15 minutes ahead of the conference call to register.

RPW Technology Announces The Launch Of Liftid Neurostimulation

Retrieved on: 
Friday, August 16, 2019
Medicine, Branches of biology, Electrotherapy, Clinical medicine, Neurotechnology, Medical devices, Neurophysiology, Neurostimulation, Transcranial direct-current stimulation, Functional electrical stimulation, Transcranial random noise stimulation, Non-invasive cerebellar stimulation

OSSINING, N.Y., Aug. 16, 2019 /PRNewswire/ --RPW Technology, LLC introduces Liftid Neurostimulation ( www.GetLiftid.com ), a transcranial direct current stimulation (tDCS) recreational device for consumers that can improve attention, productivity, and memory through mild electrical stimulation.

Key Points: 
  • OSSINING, N.Y., Aug. 16, 2019 /PRNewswire/ --RPW Technology, LLC introduces Liftid Neurostimulation ( www.GetLiftid.com ), a transcranial direct current stimulation (tDCS) recreational device for consumers that can improve attention, productivity, and memory through mild electrical stimulation.
  • Liftid uses a constant, low-level electric current, passed through two electrodes placed on the forehead area, to stimulate the brain.
  • Liftid Neurostimulation uses a safe and effective technology as an alternative to these forms of chemical stimulation.
  • RPW Technology is a New York startup dedicated to the development and marketing of transcranial electrical stimulation devices.

RPW Technology Announces the Launch of Liftid Neurostimulation (http://www.GetLiftid.com)

Retrieved on: 
Thursday, August 15, 2019
Medicine, Electrotherapy, Branches of biology, Clinical medicine, Neurotechnology, Medical devices, Neurostimulation, Neurophysiology, Transcranial direct-current stimulation, Functional electrical stimulation, Transcranial random noise stimulation, Non-invasive cerebellar stimulation

OSSINING, N.Y., Aug. 15, 2019 /PRNewswire-PRWeb/ --RPW Technology, LLC introduces Liftid Neurostimulation, a transcranial direct current stimulation (tDCS) recreational device for consumers that can improve attention, productivity, and memory through mild electrical stimulation.

Key Points: 
  • OSSINING, N.Y., Aug. 15, 2019 /PRNewswire-PRWeb/ --RPW Technology, LLC introduces Liftid Neurostimulation, a transcranial direct current stimulation (tDCS) recreational device for consumers that can improve attention, productivity, and memory through mild electrical stimulation.
  • Liftid uses a constant, low-level electric current, passed through two electrodes placed on the forehead area, to stimulate the brain.
  • Liftid Neurostimulation uses a safe and effective technology as an alternative to these forms of chemical stimulation.
  • RPW Technology is a New York startup dedicated to the development and marketing of transcranial electrical stimulation devices.

Better for Brain: Xerenoos Citicoline Backed by More Than 100 Clinical Trials

Retrieved on: 
Tuesday, August 6, 2019
Branches of biology, Neuroscience, Biology, Cholinergics, Quaternary ammonium compounds, Citicoline, Nootropics, Nucleotides, Neurophysiology, Neuroplasticity, Dementia, Brain

This can lead to memory loss, challenges in learning (neuroplasticity) and eventually cognitive impairment, however a specific form of citicoline called Xerenoos has been shown in clinical trials to provide valuable protection for the brain.

Key Points: 
  • This can lead to memory loss, challenges in learning (neuroplasticity) and eventually cognitive impairment, however a specific form of citicoline called Xerenoos has been shown in clinical trials to provide valuable protection for the brain.
  • Xerenoos, is the first and most researched oral form of citicoline, developed by Barcelona-based company Ferrer nearly 50 years ago.
  • It now has more than 100 clinical trials showing the use of citicoline in different applications for the central nervous system with more than 80% of the published clinical trials conducted on its specific trademarked citicoline, Xerenoos .
  • Consumption of Xerenoos promotes blood circulation in the brain and also enhances energy metabolism in aging brains.

NuMe TMS Clinics Now Offer FDA-Cleared Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD) in Houston

Retrieved on: 
Tuesday, August 6, 2019
Psychiatry, Neuroscience, Branches of biology, Neurotechnology, Treatment of depression, Neurophysiology, Neuropsychology, Electrotherapy, Transcranial magnetic stimulation, Obsessive–compulsive disorder, Abraham Zangen

NuMe TMS recently announced the adoption of Deep TMS across their locations in Boise and Salt Lake City as well.

Key Points: 
  • NuMe TMS recently announced the adoption of Deep TMS across their locations in Boise and Salt Lake City as well.
  • NuMe TMS is the latest adopter of this technology and joins over 100 additional providers distributing Deep TMS services for OCD nationwide.
  • In the U.S., the Companys device has been FDA cleared for the treatment of major depressive disorder (MDD) since 2013 and is now FDA cleared (De-Novo) for the treatment of Obsessive-Compulsive Disorder (OCD).
  • The Company's systems have also received CE clearance and are sold worldwide for the treatment of various brain disorders.

Media Invitation - La Jolla, CA Medical Center, Achieve TMS, Unveils State-of-the-Art/FDA-Approved Neuro-Navigation System

Retrieved on: 
Monday, August 5, 2019
Branches of biology, Neuroscience, Psychiatry, Neurotechnology, Treatment of depression, Neurophysiology, Neuropsychology, Electrotherapy, Transcranial magnetic stimulation, Major depressive disorder, TMS

This is the first such system available in San Diego.

Key Points: 
  • This is the first such system available in San Diego.
  • Achieve TMS will hold a demonstration event for interested media at 5:30 pm on Thursday August 8, 2019 at Achieve TMS La Jolla, located at 4510 Executive Drive, Suite 111, San Diego, 92121.
  • The informative event will include an introduction and medical explanation of MRI-guided brain mapping neuro-navigation transcranial magnetic stimulation (TMS) system for treating major depressive disorder (MDD) and other treatment-resistant neuropsychiatric conditions.
  • This treatment option is now available at Achieve TMS La Jolla .

Rewind Therapeutics Awarded €2.9 Million VLAIO Grant to Discover and Develop Novel Drug Candidates for Myelin-related Neurological Diseases

Retrieved on: 
Thursday, August 1, 2019
Branches of biology, Biology, Neurophysiology, Neurology, Remyelination, Multiple sclerosis, Myelin, Microelectrode array

The program is being supported with a 2.9 million grant from Flanders Innovation and Entrepreneurship (VLAIO).

Key Points: 
  • The program is being supported with a 2.9 million grant from Flanders Innovation and Entrepreneurship (VLAIO).
  • "Therapies that promote myelin repair would represent an unprecedented approach to treating multiple progressive neurological diseases such as multiple sclerosis and could prevent or reverse disability," said Ian J. Reynolds, CEO of Rewind Therapeutics.
  • "We are excited to leverage our multielectrode array (MEA) chip platform and neural interfacing technology to help find new therapeutics for neurological diseases."
  • Rewind Therapeutics is developing first-in-class remyelinating therapies for myelin-related diseases and aims to bring them into fast-track clinical development.

Rewind Therapeutics Awarded €2.9 Million VLAIO Grant to Discover and Develop Novel Drug Candidates for Myelin-related Neurological Diseases

Retrieved on: 
Thursday, August 1, 2019
Branches of biology, Biology, Neurophysiology, Neurology, Remyelination, Multiple sclerosis, Myelin, Microelectrode array

The program is being supported with a 2.9 million grant from Flanders Innovation and Entrepreneurship (VLAIO).

Key Points: 
  • The program is being supported with a 2.9 million grant from Flanders Innovation and Entrepreneurship (VLAIO).
  • "Therapies that promote myelin repair would represent an unprecedented approach to treating multiple progressive neurological diseases such as multiple sclerosis and could prevent or reverse disability," said Ian J. Reynolds, CEO of Rewind Therapeutics.
  • "We are excited to leverage our multielectrode array (MEA) chip platform and neural interfacing technology to help find new therapeutics for neurological diseases."
  • Rewind Therapeutics is developing first-in-class remyelinating therapies for myelin-related diseases and aims to bring them into fast-track clinical development.

Sleep Cycle Institute Report: New Data Suggests Jet Lag Is Only an Eastbound Problem

Retrieved on: 
Wednesday, July 31, 2019
Branches of biology, Sleep disorders, Sleep, Circadian rhythm, Neuroscience, Jet lag, Neurophysiology, Circadian rhythm sleep disorder, Insomnia

Looking at the first five days of travel, not only do people enjoy less severe jet lag when they travel west, but their quantity of sleep, quality of sleep and wake-up mood actually improve.

Key Points: 
  • Looking at the first five days of travel, not only do people enjoy less severe jet lag when they travel west, but their quantity of sleep, quality of sleep and wake-up mood actually improve.
  • Sleep Cycle asked some of the Sleep Cycle Institute panelists for further commentary about jet lag.
  • The app generates nightly sleep reports, tracks long-term sleep trends, and logs how daily activities impact sleep quality.
  • With millions of users worldwide, Sleep Cycle has also become the world's richest repository of data on global sleep habits.

Audentes Therapeutics to Release Second Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, August 6, 2019

Retrieved on: 
Tuesday, July 30, 2019
Neuromuscular junction, Neurophysiology, Skeletal muscle, Biology

SAN FRANCISCO, July 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its second quarter 2019 financial results and provide a corporate update on Tuesday, August 6, 2019.

Key Points: 
  • SAN FRANCISCO, July 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its second quarter 2019 financial results and provide a corporate update on Tuesday, August 6, 2019.
  • To access a live webcast of the conference call, please visit the Events & Presentations page within the Investor + Media section of the Audentes website at www.audentestx.com .
  • Alternatively, please call (833) 659-8620 (U.S.) or (409) 767-9247 (international) and dial the conference ID# 4244738 to access the call.
  • Audentes Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases.